Capmatinib is a really specific inhibitor that goes after the MET kinase, which is a big deal in how tumors grow, especially in a type of lung cancer called NSCLC with a certain kind of mutation. It is available in two dosages: 150 mg and 200 mg, with the recommended dose being 400 mg taken twice daily, either with or without food.
These tablets are coated and come in bottles, each with 60 tabs.
